800 related articles for article (PubMed ID: 33910399)
21. Rapid effect of benralizumab for severe asthma with chronic rhinosinusitis with nasal polyps.
Matsuno O; Minamoto S
Pulm Pharmacol Ther; 2020 Oct; 64():101965. PubMed ID: 33039667
[TBL] [Abstract][Full Text] [Related]
22. [Effectiveness of mepolizumab in patients with severe eosinophilic asthma: In a real life study].
Bulut İ; Yegin Katran Z; Yavuz D; Yıldız AB; Yakut T; Örçen C; Mersin SS
Tuberk Toraks; 2023 Jun; 71(2):148-155. PubMed ID: 37345397
[TBL] [Abstract][Full Text] [Related]
23. The Effectiveness of Biological Agents on Chronic Rhinosinusitis with Nasal Polyposis in Patients with Comorbid Asthma: A Multicenter Real-Life Study from Türkiye.
Demir M; Tunakan Dalgic C; Mete Gokmen EN; Savas R; Eroglu S; Ozden G; Orcen C; Pacaci Cetin G; Arslan B; Bilgir F; Bulut G; Akcam NY; Ozgul S; Cerci P; Coskun R; Gode S; Yilmaz I; Sin AZ
Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541174
[No Abstract] [Full Text] [Related]
24. Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count.
Bachert C; Sousa AR; Han JK; Schlosser RJ; Sowerby LJ; Hopkins C; Maspero JF; Smith SG; Kante O; Karidi-Andrioti DE; Mayer B; Chan RH; Yancey SW; Chaker AM
J Allergy Clin Immunol; 2022 May; 149(5):1711-1721.e6. PubMed ID: 35007624
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis.
Numata T; Nakayama K; Utsumi H; Kobayashi K; Yanagisawa H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2019 Oct; 19(1):176. PubMed ID: 31606052
[TBL] [Abstract][Full Text] [Related]
26. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis.
Canonica GW; Harrison TW; Chanez P; Menzella F; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; Garcia Gil E
Allergy; 2022 Jan; 77(1):150-161. PubMed ID: 33978983
[TBL] [Abstract][Full Text] [Related]
27. Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.
Comberiati P; McCormack K; Malka-Rais J; Spahn JD
J Allergy Clin Immunol Pract; 2019; 7(8):2689-2696.e2. PubMed ID: 31201938
[TBL] [Abstract][Full Text] [Related]
28. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
McDowell PJ; Diver S; Yang F; Borg C; Busby J; Brown V; Shrimanker R; Cox C; Brightling CE; Chaudhuri R; Pavord ID; Heaney LG;
Lancet Respir Med; 2021 Oct; 9(10):1174-1184. PubMed ID: 33971168
[TBL] [Abstract][Full Text] [Related]
29. Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis.
Chen S; Zhou A; Emmanuel B; Thomas K; Guiang H
Curr Med Res Opin; 2020 Nov; 36(11):1897-1911. PubMed ID: 32847417
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the Clinical Features and Laboratory Data of Patients with Severe Eosinophilic Asthma Classified as Super-Responders, Partial Responders, or Nonresponders to Mepolizumab Treatment: A Real-Life Study.
Cakmak ME; Öztop N; Yeğit OO; Özdedeoğlu Ö
Int Arch Allergy Immunol; 2023; 184(8):736-743. PubMed ID: 36996772
[TBL] [Abstract][Full Text] [Related]
31. Mepolizumab Is an Effective Option in Severe Eosinophilic Asthma Regardless of Baseline Features: Single-Center Real-Life Data.
Özdel Öztürk B; Yavuz Z; Eraslan D; Mungan D; Demirel YS; Aydın Ö; Sin BA; Bavbek S
Int Arch Allergy Immunol; 2022; 183(5):526-538. PubMed ID: 34915496
[TBL] [Abstract][Full Text] [Related]
32. Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment.
Latorre M; Bacci E; Seccia V; Bartoli ML; Cardini C; Cianchetti S; Cristofani L; Di Franco A; Miccoli M; Puxeddu I; Celi A; Paggiaro P
Ther Adv Respir Dis; 2020; 14():1753466620965151. PubMed ID: 33263506
[TBL] [Abstract][Full Text] [Related]
33. [A real world study of anti-IgE monoclonal antibody in the treatment of allergic united airway disease].
Sui HJ; Zhen Z; Wang QG; Cong TC; Huang JJ; Hu Y
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Feb; 57(2):273-280. PubMed ID: 36797588
[No Abstract] [Full Text] [Related]
34. Benefits of biologic therapy administered for asthma on co-existent chronic rhinosinusitis: A real-world study.
Bajpai S; Marino MJ; Rank MA; Donaldson AM; O'Brien EK; Lal D
Int Forum Allergy Rhinol; 2021 Aug; 11(8):1152-1161. PubMed ID: 33527730
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
Gevaert P; Omachi TA; Corren J; Mullol J; Han J; Lee SE; Kaufman D; Ligueros-Saylan M; Howard M; Zhu R; Owen R; Wong K; Islam L; Bachert C
J Allergy Clin Immunol; 2020 Sep; 146(3):595-605. PubMed ID: 32524991
[TBL] [Abstract][Full Text] [Related]
36. The Role of Fractional Exhaled Nitric Oxide in Diagnosing Asthmatic Type 2 Chronic Rhinosinusitis With Nasal Polyps.
Park JA; Cha H; Yang SK; Ryu HT; Kim DW; Hong SN; Yang MS; Kim DW
Am J Rhinol Allergy; 2023 Sep; 37(5):524-530. PubMed ID: 37160729
[TBL] [Abstract][Full Text] [Related]
37. Mepolizumab improves sense of smell in severe chronic rhinosinusitis with nasal polyps: SYNAPSE.
Mullol J; Lund VJ; Wagenmann M; Han JK; Sousa AN; Smith SG; Mayer B; Chan RH; Fokkens WJ
Rhinology; 2024 Jun; 62(3):320-329. PubMed ID: 38217844
[TBL] [Abstract][Full Text] [Related]
38. [Impact of reslizumab on the course of chronic rhinosinusitis in patients with eosinophilic asthma].
Boiko NV; Lodochkina OE; Kit MM; Kuleshova VG; Nedashkovskaya NG
Vestn Otorinolaringol; 2021; 86(2):43-48. PubMed ID: 33929151
[TBL] [Abstract][Full Text] [Related]
39. Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial.
Bachert C; Sousa AR; Lund VJ; Scadding GK; Gevaert P; Nasser S; Durham SR; Cornet ME; Kariyawasam HH; Gilbert J; Austin D; Maxwell AC; Marshall RP; Fokkens WJ
J Allergy Clin Immunol; 2017 Oct; 140(4):1024-1031.e14. PubMed ID: 28687232
[TBL] [Abstract][Full Text] [Related]
40. Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response.
Caminati M; Cegolon L; Vianello A; Chieco Bianchi F; Festi G; Marchi MR; Micheletto C; Mazza F; Tognella S; Senna G
Expert Rev Respir Med; 2019 Dec; 13(12):1205-1212. PubMed ID: 31592700
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
